Achieve Life Sciences to Release Q2 Financials and Hold Conference Call/Webcast on August 13, 2024

SEATTLE and VANCOUVER, British Columbia, July 25, 2024 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a pharmaceutical company in the advanced stages of developing cytisinicline for smoking cessation and nicotine dependence, has announced plans to release its financial results for the second quarter of 2024. The company will also provide an update on the progress of the cytisinicline development program on Tuesday, August 13, 2024, at 4:30 PM EDT.

Achieve Life Sciences is focused on tackling the global health crisis caused by smoking and nicotine addiction. In the United States alone, approximately 28 million adults smoke cigarettes. Tobacco use remains the leading cause of preventable death worldwide, accounting for over eight million deaths annually on a global scale, including nearly half a million in the United States. Smoking is responsible for 87% of lung cancer deaths, 61% of deaths from pulmonary disease, and 32% of deaths from coronary heart disease.

In addition, e-cigarette usage, or vaping, is on the rise with more than 11 million adults in the United States using these devices. Alarmingly, about 2.1 million middle and high school students in the United States reported using e-cigarettes in 2023. Currently, there are no FDA-approved treatments specifically designed to aid in quitting e-cigarettes.

Cytisinicline, a plant-based alkaloid, displays a high binding affinity for the nicotinic acetylcholine receptor. It is believed to help in smoking and e-cigarette cessation by interacting with nicotine receptors in the brain. This interaction may reduce the severity of withdrawal symptoms and lessen the reward and satisfaction derived from nicotine products. Cytisinicline is still an investigational product and has not yet received approval from the Food and Drug Administration for any use in the United States.

Achieve Life Sciences continues to work towards the development and commercialization of cytisinicline, aiming to address the significant health threats posed by nicotine addiction. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!